BioSpace News Archive

Bio Conscious Technologies Inc. a Prevention-as-a-Service™ technology company using machine learning to predict and manage chronic diseases, is announcing that its Diabits users have experienced positive blood glucose outcomes following the COVID-19 lockdown.

Trial supports Abbott’s focus on being the best partner for electrophysiologists treating people living with atrial fibrillation

Evolution Research Group, a leading independent clinical research site company with a focus on improving the quality and delivery of complex, specialized trials across 15 geographically diverse clinical trial sites in the United States, announces the appointment of William Martin, Ph.D. to the position of Chief Scientific Officer.

Quotient Limited, a commercial-stage diagnostics company, published the latest investor presentation associated with the earnings call for fiscal quarter ended June 30, 2020.

Researchers Use Menarini’s Liquid Biopsy Technology to Find Genetic Alterations in Cancer Cells that May Improve Prognosis and Treatment

Policy undermines patient care and further strains health care system weakened from COVID-19 pandemic

Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the appointment of Robert J. Spiegel, MD, FACP, a renowned biotech and pharmaceutical executive, to its Board of Directors. “We are thrilled to add an industry executive with Dr. Spiegel’s deep drug development expertise to our Board

BryoLogyx, Inc. today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), to conduct a Phase I clinical trial with bryostatin-1 in pediatric and young adult patients with relapsing or refractory CD22 expressing acute lymphoblastic leukemia (ALL) and lymphoma. The study, expected to start later this year, will be the first in patients to eva

JanOne Inc. (Nasdaq: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, announces a internal name change for its current drug candidate from TV1001SR to JAN101, soon to enter Phase 2b clinical trials as a potential treatment Peripheral A

Researchers have found Menopause Relief PLUS, a proprietary combination of Black Cohosh EP40™ and Rhodiola EPR-7™ delivered a stunning 71.2% reduction in menopause symptoms in just 12 weeks.